Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity (NASDAQ:CELC) has announced the pricing of two underwritten public offerings. The first is a $175 million offering ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

董事大卫·达尔维（David Dalvey）于2025年7月28日报告出售了Celcuity Inc.（纳斯达克：CELC）的股份，根据向美国证券交易委员会提交的表格4文件显示。这些销售总计4,818,369美元，执行价格在43.2974美元至46.0501美元之间。根据 InvestingPro ...

Shares of Celcuity Inc CELC +17.6% + Free Alerts rose sharply in pre-market trading after the company announced it will ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results ...

这家临床阶段生物技术公司还提供以每份权证37.999美元购买最多400,000股股票的预付费权证。承销商获得了30天期权，可额外购买价值2625万美元的可转换债券和最多335,526股额外股票。

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...